Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction

NCT01298219 is registered in ClinicalTrials.gov with Sucampo Pharma Americas, LLC as lead sponsor.

NCT NCT01298219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01298219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Lead sponsor
Sucampo Pharma Americas, LLC
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2010
Completion date
November 30, 2011
Enrollment
439 (actual)
Sites
142

Conditions

As the registry lists them; a condition with its own page is linked.

opioid-induced bowel dysfunction